STAT+: ‘I don’t know anybody who wants their health disrupted’: Ken Frazier steps out in new venture capital role

Healthcare Tech

Former Merck CEO Ken Frazier, famous for building the drugmaker into one of the world’s biggest cancer companies, shed his pharma garb in his first public appearance since starting a new role with the venture capital giant General Catalyst.

In July, General Catalyst appointed Frazier, who remains the executive chairman of Merck, as head of the firm’s “health assurance initiatives,” which seek to more create equitable and affordable health care through consumer-centric offerings. The splashy hire of Frazier, who is leading the firm’s newly created $600 million Health Assurance Fund, rocketed General Catalyst to prominence in the health care space. The firm has made numerous investments in companies including Livongo and Oscar — not to mention its well-known successful bets on tech firms like Airbnb, Stripe, Snap, and others.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Articles You May Like

After internal review, another Talkspace exec resigns
Healthy Key Lime Pie Recipe (Gluten-Free & Paleo)
Sweet Potato Brownies Recipe – Dr. Axe
GSK joins NASH chase, paying $120M up front for rights to Arrowhead RNAi drug
Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions